Zai Lab Ltd (ZLAB)

$27.98

+0.49

(+1.78%)▲

Live

Performance

  • $27.24
    $28.10
    $27.98
    downward going graph

    2.64%

    Downside

    Day's Volatility :3.06%

    Upside

    0.43%

    downward going graph
  • $13.48
    $31.22
    $27.98
    downward going graph

    51.82%

    Downside

    52 Weeks Volatility :56.82%

    Upside

    10.38%

    downward going graph

Returns

PeriodZai Lab LtdSector (Health Care)Index (Russel 2000)
3 Months
39.54%
3.6%
0.0%
6 Months
83.39%
10.2%
0.0%
1 Year
14.35%
19.6%
0.0%
3 Years
-72.43%
16.8%
-23.0%

Highlights

Market Capitalization
2.7B
Book Value
$7.18
Earnings Per Share (EPS)
-3.1
Wall Street Target Price
49.82
Profit Margin
-92.45%
Operating Margin TTM
-75.68%
Return On Assets TTM
-21.13%
Return On Equity TTM
-36.46%
Revenue TTM
322.7M
Revenue Per Share TTM
3.32
Quarterly Revenue Growth YOY
45.9%
Gross Profit TTM
-145.4M
EBITDA
-343.6M
Diluted Eps TTM
-3.1
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.97
EPS Estimate Next Year
-1.79
EPS Estimate Current Quarter
-0.71
EPS Estimate Next Quarter
-0.69

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Zai Lab Ltd(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 78.06%

Current $27.98
Target $49.82

Company Financials

FY18Y/Y Change
Revenue
129.5K
-
Net Income
-139.1M
↑ 176.03%
Net Profit Margin
-107.4K%
-
FY19Y/Y Change
Revenue
13.0M
↑ 9930.55%
Net Income
-183.4M
↑ 31.85%
Net Profit Margin
-1.4K%
↑ 106021.4%
FY20Y/Y Change
Revenue
49.0M
↑ 277.04%
Net Income
-298.2M
↑ 62.6%
Net Profit Margin
-609.02%
↑ 803.14%
FY21Y/Y Change
Revenue
144.3M
↑ 194.77%
Net Income
-692.4M
↑ 132.24%
Net Profit Margin
-479.82%
↑ 129.2%
FY22Y/Y Change
Revenue
215.0M
↑ 49.01%
Net Income
-482.0M
↓ 30.39%
Net Profit Margin
-224.14%
↑ 255.68%
FY23Y/Y Change
Revenue
266.7M
↑ 24.03%
Net Income
-334.6M
↓ 30.58%
Net Profit Margin
-125.46%
↑ 98.68%
Q1 FY23Q/Q Change
Revenue
62.8M
↑ 0.31%
Net Income
-28.8M
↑ 9.61%
Net Profit Margin
-45.81%
↓ 3.89%
Q2 FY23Q/Q Change
Revenue
68.9M
↑ 9.66%
Net Income
-120.9M
↑ 320.27%
Net Profit Margin
-175.56%
↓ 129.75%
Q3 FY23Q/Q Change
Revenue
69.2M
↑ 0.53%
Net Income
-69.2M
↓ 42.8%
Net Profit Margin
-99.89%
↑ 75.67%
Q4 FY23Q/Q Change
Revenue
65.8M
↓ 4.91%
Net Income
-95.4M
↑ 38.0%
Net Profit Margin
-144.96%
↓ 45.07%
Q1 FY24Q/Q Change
Revenue
87.1M
↑ 32.38%
Net Income
-53.5M
↓ 43.97%
Net Profit Margin
-61.36%
↑ 83.6%
Q2 FY24Q/Q Change
Revenue
100.5M
↑ 15.32%
Net Income
-80.3M
↑ 50.13%
Net Profit Margin
-79.87%
↓ 18.51%
FY18Y/Y Change
Total Assets
302.0M
↑ 20.97%
Total Liabilities
50.9M
↑ 251.96%
FY19Y/Y Change
Total Assets
355.2M
↑ 17.61%
Total Liabilities
60.5M
↑ 18.83%
FY20Y/Y Change
Total Assets
1.3B
↑ 265.37%
Total Liabilities
128.3M
↑ 112.08%
FY21Y/Y Change
Total Assets
1.6B
↑ 24.07%
Total Liabilities
230.0M
↑ 79.28%
FY22Y/Y Change
Total Assets
1.2B
↓ 24.21%
Total Liabilities
174.5M
↓ 24.11%
FY23Y/Y Change
Total Assets
1.0B
↓ 15.07%
Total Liabilities
240.2M
↑ 37.6%
Q1 FY23Q/Q Change
Total Assets
1.2B
↓ 4.1%
Total Liabilities
168.8M
↓ 3.27%
Q2 FY23Q/Q Change
Total Assets
1.1B
↓ 5.44%
Total Liabilities
174.1M
↑ 3.1%
Q3 FY23Q/Q Change
Total Assets
1.0B
↓ 5.67%
Total Liabilities
162.7M
↓ 6.52%
Q4 FY23Q/Q Change
Total Assets
1.0B
↓ 0.71%
Total Liabilities
240.2M
↑ 47.61%
Q1 FY24Q/Q Change
Total Assets
988.4M
↓ 4.62%
Total Liabilities
226.3M
↓ 5.79%
Q2 FY24Q/Q Change
Total Assets
987.4M
↓ 0.11%
Total Liabilities
283.2M
↑ 25.16%
FY18Y/Y Change
Operating Cash Flow
-97.5M
↑ 201.35%
Investing Cash Flow
-212.6M
↑ 1937.13%
Financing Cash Flow
144.1M
↓ 23.27%
FY19Y/Y Change
Operating Cash Flow
-191.0M
↑ 95.83%
Investing Cash Flow
-14.9M
↓ 92.99%
Financing Cash Flow
219.3M
↑ 52.14%
FY20Y/Y Change
Operating Cash Flow
-216.1M
↑ 13.11%
Investing Cash Flow
-554.8M
↑ 3625.69%
Financing Cash Flow
1.1B
↑ 416.38%
FY21Y/Y Change
Operating Cash Flow
-549.2M
↑ 154.21%
Investing Cash Flow
250.0M
↓ 145.05%
Financing Cash Flow
820.2M
↓ 27.57%
FY22Y/Y Change
Operating Cash Flow
-367.6M
↓ 33.06%
Investing Cash Flow
420.0M
↑ 68.04%
Financing Cash Flow
-1.7M
↓ 100.21%
Q1 FY23Q/Q Change
Operating Cash Flow
-69.3M
↓ 36.6%
Investing Cash Flow
42.7M
↓ 1076.49%
Financing Cash Flow
-3.9M
↑ 1852.76%
Q2 FY23Q/Q Change
Operating Cash Flow
-58.7M
↓ 15.28%
Investing Cash Flow
42.7M
↑ 0.0%
Financing Cash Flow
-1.5M
↓ 61.58%

Technicals Summary

Sell

Neutral

Buy

Zai Lab Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Zai Lab Ltd
Zai Lab Ltd
32.67%
83.39%
14.35%
-72.43%
-16.27%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Zai Lab Ltd
Zai Lab Ltd
NA
NA
NA
-2.97
-0.36
-0.21
NA
7.18
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Zai Lab Ltd
Zai Lab Ltd
Buy
$2.7B
-16.27%
NA
-92.45%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Zai Lab Ltd

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 65.83M → 100.50M (in $), with an average increase of 18.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -53.47M → -80.27M (in $), with an average decrease of 50.1% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 67.9%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 117.2%

Institutional Holdings

  • Wellington Management Company LLP

    7.15%

  • HHG PLC

    6.55%

  • Capital World Investors

    5.33%

  • Woodline Partners LP

    2.34%

  • Viking Global Investors LP

    2.05%

  • BAMCO Inc

    1.80%

Company Information

zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve

Organization
Zai Lab Ltd
Employees
2175
CEO
Dr. Ying Du Ph.D.
Industry
Health Technology

Discover More

FAQs